Over the past several years, long non-coding RNAs (lncRNAs) have attracted more and more attention due to their special functions. They are vital biomarkers in multiple diseases. LncRNA HOMEOBOX A11 (HOXA11) has been found to be aberrantly expressed in some kinds of malignant tumors. In this study, we mainly discuss the oncogenic role of it in promoting malignant progression and chemoresistance in lung 
chemoresistance to chemotherapy result in mortality for most patients. 6, 7 Chemoresistance is a huge problem in chemotherapy. So in this study, we focused on how to sensitize LUAD to cisplatin.
Long non-coding RNA (lncRNA) is known as a type of noncoding RNA with over 200 nucleotides in length and non-protein coding ability. 8 It has been certified that abnormal expression of lncRNAs plays a vital role in the progression of various cancers such as ovarian cancer, 9 colon cancer 10 and gastric cancer. 11 Therefore, studying lncRNAs may be of great value in exploring the occurrence and development of tumors. Although so many lncRNAs have been reported in human cancers, countless lncRNAs still await investigation. LncRNA HOMEO-BOX A11 (HOXA11) antisense RNA (HOXA11-AS) has been recorded in some cancer reports. According to all previous reports, we knew that HOXA11-AS could positively modulate progression and development of several types of human cancers, such as colorectal cancer, 12 hepatocellular carcinoma, 13 glioma 14 and breast cancer. 15 The specific role of HOXA11-AS in lung adenocarcinoma still lacks investigation. In this study, we tried to reveal the specific function and mechanism of HOXA11-AS in lung adenocarcinoma. Functional experiments were utilized to analyze the oncogenic role of HOXA11-AS1. The investigation was designed to develop a molecular mechanism centered around HOXA11-AS1. Finally, rescue assays were used to demonstrate the effects of the HOXA11-AS1-miR-454-3p-Stat3 pathway on the progression and cisplatin resistance of LUAD.
| MATERIALS AND METHODS

| TCGA database
The expression profile of HOXA11-AS1 in LUAD tissues and corresponding normal tissues from The Cancer Genome Atlas (TCGA) database (https://cancergenome.nih.gov/) were analyzed. Tissues samples in TCGA database were divided into two groups (HOXA11-AS high expression group: n = 267; HOXA11-AS low expression group: n = 268). A survival curve was generated to analyze the correlation between HOXA11-AS expression and the overall survival of LUAD patients.
| Cell lines LUAD cells (A549 and H157) and HEK-293T cells used in this study
were obtained from the Institute of Cell Research, Chinese Academy of Sciences, Shanghai, China. Cells were cultured in RPMI-1640 medium (Invitrogen, Carlsbad, CA, USA) with 10% of fetal bovine serum (FBS) added. Then, cells were maintained in RPMI-1640 medium (Invitrogen) which was also supplemented with 10% FBS. Plates used to seed cells were incubated at 37°C in a humidified atmosphere with 5% CO 2 .
| Development of cisplatin-resistant cell lines
According to the methods introduced by Barr et al., 16 we continuously treated parental LUAD cells (A549 and H157) with a gradually increasing dose of cisplatin for half a year. In short, cells were treated with 1 μmol/L cisplatin for 3 days. 
| Transfection
We bought miR-454-3p mimic, miR-454-3p inhibitor and negative control from Applied Biological Materials (ABM, Vancouver, British Columbia, Canada). According to the instructions of the manufacturer, the Lipofectamine 2000 kit (Invitrogen) was utilized for all necessary transfections.
| Plasmid construction
The cDNA encoding HOXA11-AS was PCR amplified and subcloned into the pLent-GIII-CMV-Puro vector (ABM, Canada), which was named pLent-HOXA11-AS. The short hairpin RNA (shRNA) was constructed with sequence specifically targeted to HOXA11-AS, which was obtained from ABM (Canada). The specific shRNAs for HOXA11-AS and signal transducer and activator of transcription 3 (Stat3) were synthesized by ABM (Canada). The plasmid pLent-HOXA11-AS was stably transfected into cells and screened with Puromycin (2 μg/mL) for 4 weeks. The sequences of sh-HOXA11-AS are shown in Table S1 .
| Isolation of RNA and quantitative RT-PCR
According to the user's manual, Trizol reagent (Invitrogen) was adopted to isolate total RNA from cells. Reverse transcription (RT) was finished by means of PrimeScript RT reagent Kit (Takara, Dalian, China). Based on the instructions for use, we conducted quantitative RT-PCR with SYBR Prime Script RT-PCR Kits (Takara, Dalian, China).
Relative quantification (2 −ΔΔCt method) was employed to calculate fold changes, which was normalized to GAPDH. All assays were carried out in triplicate. All primers are displayed in Table S1 .
| MTT assay
In order to detect cell viability, 96-well plates (3 × 10 3 cells per well)
were utilized to immediately seed cells or 1 day after transfection.
After the indicated drug combinations were treated for 2 days, cell viability was assessed by means of MTT assay. 
| Immunofluorescence
Glass coverslips of 6-well plates were applied to seed cells, for the fixation and permeation of cells; 4% formaldehyde solution and 0.5%
Triton X-100/PBS were separately put into use. In order to block cells, we added 5% BSA PBS for 1 hour at room temperature. Next, the primary antibody was incubated at 4°C overnight, followed with 1-hour incubation of fluorescent-dye conjugated secondary antibody (Invitrogen), and then, we stained cells with DAPI. Finally, images
were obtained with a reverse-fluorescence microscope.
| Flow cytometry analysis assay
Flow cytometry was applied to measure cell apoptosis. Briefly, cells were cultured in a normal medium and transfected with corresponding plasmids. Cells were collected after transfection for 48 hours.
According to the user's guide, PE Annexin V apoptosis detection kits (BD Pharmingen, San Diego, CA, USA) were used for determining cell apoptosis. Finally, cell apoptosis was assessed by using flow cytometry (EPICS, XL-4, Beckman, Brea, CA, USA).
| Subcellular fractionation assay
We utilized NE-PER Nuclear and Cytoplasmic Extraction Reagents 
| RNA-binding protein immunoprecipitation
In accordance with the manufacturer's protocol, both the Magna 
| Dual-luciferase reporter assay
The 
| Western blotting analysis
Total cell lysates were maintained in a 1× sodium dodecyl sulfate buffer for preparation. Total protein was dissolved by sodium dodecyl sulfate-polyacrylamide gelelectrophoresis and then was transferred onto nitrocellulose membranes. Next, the membrane was sealed with 5%
non-fat milk and incubated with primary antibodies at 4°C overnight.
After incubation with antibodies (E-cadherin, β-catenin, N-cadherin, Vimentin, Snail, Twist, Cleaved caspase-3, Cleaved caspase-9, Totalcaspase-3, Total caspase-9, Stat3, GAPDH) (Abcam, Hong Kong, China), the blots were incubated with goat anti-rabbit secondary antibody (Abcam). Chemiluminescence brought them out.
| Statistical analysis
Data are displayed as the means ± SD error. All data were obtained from more than two independent experiments. Statistical analysis was made by SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). Student's t test was performed to make comparisons between two groups. On the other hand, one-way ANOVA was used to analyze the comparisons among multiple groups. All tests were bidirectional.
All these data with P values less than .05 were recognized as statistically significant.
| RESULTS
| Dysregulation of HOXA11-AS is associated with cisplatin resistance of LUAD cells
The expression level of LUAD in the LUAD samples of TCGA database was analyzed. Obviously, HOXA11-AS was expressed much higher in LUAD tissues ( Figure 1A ). Subsequently, LUAD samples in TCGA database were divided into two groups in accordance with the mean value of HOXA11-AS expression. A survival curve was generated to reveal the correlation between HOXA11-AS expression and the overall survival of LUAD patients. It could be observed that the overall survival rate in the high expression group (n = 267) was lower than that in the low expression group (n = 268) ( Figure 1B ).
Since we aimed to study the effect of HOXA11-AS on the cisplatin sh-HOXA11-AS ( Figure 1H ). All these findings indicated that HOXA11-AS is a poor prognostic factor for LUAD patients and a potential biomarker for cisplatin resistance.
| Effects of HOXA11-AS on chemoresistance of LUAD cells
Considering the potential oncogenic role of HOXA11-AS, we designed and conducted functional assays in both parental cells and The IC 50 value of cisplatinresistant LUAD cells was detected after HOXA11-AS was knocked down. Error bars represent the mean ± SD of at least three independent experiments. *P < .05, **P < .01, ***P < .001 vs control group ZHAO ET AL.
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cisplatin-resistant cells which were treated with or without cisplatin.
The parental cells were treated with cisplatin at a density of 1 μg/ mL, while the cisplatin-resistant cells were treated with cisplatin at a concentration of 3 μg/mL. At first, colony formation assays revealed that the proliferative ability was enhanced after A549 and H157 cells were transfected with pLent-HOXA11-AS. The cell proliferation was affected in a dose-dependent manner (Figures 2A and 3A) . As for A549-CR and H157-CR cells, the proliferative ability was weakened after cells were transfected with sh-HOXA11-AS. The inhibitory effect was more obvious in the cisplatin group ( Figures 2B   and 3B ). Flow cytometry analysis disclosed that the apoptotic rate of A547 and H157 cells transfected with pLent-HOXA11-AS was decreased in a dose-dependent manner ( Figures 2C and 3C ). As for cisplatin-resistant cells (A549-CR and H157-CR), the apoptotic rate in the cisplatin group was higher than that in the non-cisplatin group when both of the groups were simultaneously treated with sh-HOXA11-AS ( Figures 2D and 3D) . For further confirmation, we also examined the levels of apoptosis-related proteins with western (F) Western blot analysis tested the protein levels of apoptosis-related proteins in the cisplatin group or in the non-cisplatin group after A549-CR cells were treated with sh-HOXA11-AS. Error bars represent the mean ± SD of at least three independent experiments. *P < .05, **P < .01 vs control group blotting assay. The results showed that the levels of cleaved-caspase-3 and cleaved-caspase-9 in the cisplatin group and non-cisplatin group were decreased when transfected with pLent-HOXA11-AS ( Figures 2E and 3E ). Western blot analysis also showed the protein levels of cleaved-caspase-3 and cleaved-caspase-9 were much higher in the cisplatin group than that the in non-cisplatin group ( Figures 2F   and 3F ). Therefore, we concluded that HOXA11-AS can affect the chemoresistance of LUAD cells.
| HOXA11-AS affects the metastasis and EMT process in parental cells and cisplatin-resistant cells
Here, we continued to explore the influence of HOXA11-AS on cell metastasis and epithelial mesenchymal transition (EMT). According to the results of the transwell assay, metastatic ability of A459 and H157 cells was significantly enhanced by HOXA11-AS overexpression ( Figure 4A ). However, the metastatic ability of A459-CR and
F I G U R E 3 The effects of HOMEOBOX A11 antisense RNA (HOXA11-AS) on the chemoresistance of lung adenocarcinoma (LUAD) cells. (A)
Colony formation assays measured the proliferation ability of H157 cells in the cisplatin group (1 μg/mL) and non-cisplatin group after HOXA11-AS was overexpressed. (B) The proliferation of H157-CR cells was evaluated in the cisplatin group (3 μg/mL) and non-cisplatin group after HOXA11-AS was downregulated. (C) Flow cytometry analysis examined the apoptotic rate in both cisplatin and non-cisplatin groups after H157 cells were transfected with pLent-HOXA11-AS. (D) Flow cytometry analysis examined the apoptotic rate in both cisplatin and noncisplatin groups after H157-CR cells were transfected with short hairpin RNA (sh)-HOXA11-AS. (E) Western blot analysis tested the protein levels of apoptosis-related proteins in the cisplatin group or in the non-cisplatin group after H157 cells were treated with pLent-HOXA11-AS. (F) Western blot analysis tested the protein levels of apoptosis-related proteins in the cisplatin group or in the non-cisplatin group after H157-CR cells were treated with sh-HOXA11-AS. Error bars represent the mean ± SD of at least three independent experiments. *P < .05, **P < .01 vs control group ZHAO ET AL.
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H157-CR cells was weakened by silenced HOXA11-AS (Figure 4B
)
| HOXA11-AS is a sponge of miR-454-3p
It is widely acknowledged that lncRNAs can act as ceRNA to increase the expressions of the underlying target mRNAs through sponging (Table S2 ). To make further confirmation, we applied quantitative RT-PCR analysis to measure the expression changes of these miRNAs when HOXA11-AS was downregulated. It was found that only miR-454-3p could be observably affected by silenced HOXA11-AS (Table S2 ), indicating that miR-454-3p might be involved in the function mediated by HOXA11-AS. Later, RIP assay was performed in A549-CR and H157-CR cells by using the antibody against Ago2. As elucidated in Figure 5B , HOXA11-AS and miR-454-3p were obviously enriched in Ago2-immunoprecipitation. According to the Figure 5F ), whereas, the expression of HOXA11-AS in A549 and H157 cells was enhanced by miR-454-3p inhibitor ( Figure 5G ).
Taken together, HOXA11-AS is a sponge of miR-454-3p.
| HOXA11-AS positively modulates Stat3 through sequestering miR-454-3p
It has been reported that miR-454-3p can inhibit chondrosarcoma cell growth by targeting Stat3. 17 Here, we hypothesized that the 
| Effect of HOXA11-AS-miR-454-3p-Stat3 axis on cisplatin resistance of LUAD cells
To prove the function of this ceRNA pathway in our study, we 
| DISCUSSION
As one of the most frequent malignant tumors for human beings, NSCLC is well-known for its high mortality and poor survival rate worldwide. 1 Although various chemotherapy drugs have been developed to treat lung cancers, the resistance to these drugs is a vital factor in the poor prognosis of lung cancer patients. 18, 19 Cisplatin is a common chemical compound, which is widely used in chemotherapy for its high efficiency in the early therapeutic stage. Nevertheless, with the development of malignance, the sensitivity of cancerous cells to cisplatin is weakened, thus resistance to this drug emerges. This situation can be observed in many therapeutic processes of cancers. Therefore, it is urgent to study the specific molecular mechanism by which cisplatin resistance is promoted. The Error bars represent the mean ± SD of at least three independent experiments. **P < .01 vs control group cancers. Much evidence has suggested that lncRNAs partly affect drug resistance in cancer cells through these two mechanisms. [20] [21] [22] [23] [24] [25] According to TCGA database, lncRNA HOXA11-AS was expressed much higher in LUAD tissues than that in corresponding non-tumor 27 CASC2/miR-21 pathway has been found to be able to affect the sensitivity to cisplatin in cervical cancer. 28 All the above reports provide proof to demonstrate the interaction between lncRNAs and miRNAs in the cisplatin resistance of cancers.
Here, miR-454-3p was certified to be a target miRNA of HOXA11-AS by applying bioinformatics analysis and mechanism experiments.
Since lncRNAs can act as a ceRNA by competitively binding miRNAs, 
